Skip to main content

Frost & Sullivan Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner

By January 8, 2024January 19th, 2024Company News

Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner – Affecting Drug Development Schedules & Financial Plans

Avance Clinical, the leading Australian and North American CRO for biotechs announced today that new industry analysis shows 60-65% of US biotechs face challenges identifying the right sized CRO partner that can deliver at every phase of their drug development program. The report found this directly affected clinical programs and budgets.

The report also found that 50% of biotechs engaged with more than one CRO over the course of their clinical program potentially impacting knowledge transfer, timelines and budget.

To download this white paper, please submit your details on the form.

Find out more:

FILL IN THE FORM TO DOWNLOAD THE WHITE PAPER

By filling in this form you consent to Avance Clinical contacting you. Read our Privacy Policy
This field is for validation purposes and should be left unchanged.

[/one_third]

DOWNLOAD OUR LATEST WHITEPAPER

Why 65% of US Biotechs Struggle to Identify Suitable CRO Partner

By filling in this form you consent to Avance Clinical contacting you. Read our Privacy Policy
This field is for validation purposes and should be left unchanged.

This will close in 0 seconds